Pharmacological and clinical evaluation of deferasirox formulations for treatment tailoring
Abstract Deferasirox (DFX) is the newest among three different chelators available to treat iron overload in iron-loading anaemias, firstly released as Dispersible Tablets (DT) and more recently replaced by Film-Coated Tablets (FCT). In this retrospective observational study, pharmacokinetics, pharm...
Main Authors: | Andrea Piolatto, Paola Berchialla, Sarah Allegra, Silvia De Francia, Giovanni Battista Ferrero, Antonio Piga, Filomena Longo |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-06-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-91983-w |
Similar Items
-
Ineffective Erythropoiesis in β-Thalassaemia: Key Steps and Therapeutic Options by Drugs
by: Filomena Longo, et al.
Published: (2021-07-01) -
A Study of Knowledge about Deferasirox and Behavior of Taking Deferasirox in Patients with β-Thalassemia Major
by: Pei-Yi Mei, et al.
Published: (2012) -
From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox
by: Giuseppe A. Palumbo, et al.
Published: (2021-10-01) -
Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload
by: Wu D, et al.
Published: (2018-05-01) -
The Clinical Evaluation of Deferasirox Effect on Hematological Parameters after Lead Administration
by: Maliheh Zahmati, et al.
Published: (2016-12-01)